Related Experiment Video
Updated: Aug 8, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 27, 2013
Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation
Y Liu1, W W Cruikshank, T O'Loughlin
1Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Insights
Interleukin-16 (IL-16) binds to the D4 domain of CD4, activating immune cells. This interaction, mediated by specific peptides, explains IL-16
Area of Science:
- Immunology
- Molecular Biology
- Cell Biology
Background:
- Interleukin-16 (IL-16) is known to activate CD4(+) cells, suggesting a direct interaction with the CD4 molecule.
- The high conservation of IL-16 structure and function across species implies a conserved binding site on CD4.
Purpose of the Study:
- To identify the specific region on CD4 responsible for IL-16 binding.
- To elucidate the mechanism by which IL-16 interacts with CD4 and affects immune responses.
Main Methods:
- Comparative analysis of human and various species' CD4 amino acid sequences to identify conserved regions.
- Synthesis and testing of murine CD4 domain 4 (D4) oligopeptides for their ability to inhibit IL-16 chemoattractant activity and binding to CD4 in vitro.
Main Results:
- Immunoglobulin-like domain 4 (D4) of CD4 was identified as the most conserved extracellular region.
- Three D4 peptides (A, B, and C) inhibited IL-16 chemoattractant activity, with peptide B being most potent.
- Peptides A and B blocked IL-16 binding to CD4 in vitro, indicating the D4 domain contains the IL-16 binding site.
- The IL-16 binding site within D4 overlaps with residues involved in CD4 dimerization, explaining IL-16's inhibition of mixed lymphocyte reactions.
Conclusions:
- CD4 possesses an IL-16 binding site within its D4 domain.
- This binding interaction provides a mechanistic basis for IL-16's known inhibitory effect on mixed lymphocyte reactions.
Abstract:
Interleukin-16 (IL-16) activates CD4(+) cells, possibly by direct interaction with CD4. IL-16 structure and function are highly conserved across species, suggesting similar conservation of a putative IL-16 binding site on CD4. Comparison of the human CD4 amino acid sequence with that of several different species revealed that immunoglobulin-like domain 4 is the most conserved extracellular region. Potential interaction of this domain with IL-16 was studied by testing murine D4 sequence-based oligopeptides for inhibition of IL-16 chemoattractant activity and inhibition of IL-16 binding to CD4 in vitro. Three contiguous 12-residue D4 region peptides (designated A, B, and C) blocked IL-16 chemoattractant activity, with peptide B the most potent. Peptides A and B were synergistic for inhibition, but peptide C was not. Peptides A and B also blocked IL-16 binding to CD4 in vitro, whereas peptide C did not. CD4, in addition to its known function as a receptor for major histocompatibility complex class II, contains a binding site for IL-16 in the D4 domain. The D4 residues required for IL-16 binding overlap those previously shown to participate in CD4-CD4 dimerization following class II major histocompatibility complex binding, providing a mechanistic explanation for the known function of IL-16 to inhibit the mixed lymphocyte reaction.
More Related Videos
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

